Literature DB >> 3553892

Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum.

G X Chen, C Mueller, M Wendlinger, J W Zolg.   

Abstract

Dihydrofolate reductase (DHFR) (5,6,7,8-tetrahydrofolate: NADPH+-oxidoreductase; EC 1.5.1.3) was partially purified by affinity chromatography from three clones of the human malaria parasite Plasmodium falciparum. The three clones were representative of pyrimethamine-sensitive (clone 3D7) and pyrimethamine-resistant (clone HB3 and clone 7G8) parasites with ID50 values of 0.53 nM (3D7), 210 nM (HB3), and 540 nM (7G8), when tested in vitro against the drug. The specific activities of the partially purified DHFR differed by less than a factor of 2 between the sensitive clone 3D7 (442 +/- 39 nmol min-1 mg-1 protein) and the resistant clones HB3 (634 +/- 25 nmol min-1 mg-1 protein) and 7G8 (565 +/- 85 nmol min-1 mg-1 protein). The number of catalytic sites in partially purified DHFR from the three clones was similar and ranged from 151 to 194 pmol mg-1 protein. The Km value for NADPH was similar in all three clones (4.5-11.6 microM). The Km value for dihydrofolate was altered 13-fold comparing the sensitive clone 3D7 (3.2 +/- 0.6 microM) with the resistant clone HB3 (42.6 +/- 1.6 microM), with the Km for the resistant clone 7G8 falling in between (11.9 +/- 1.2 microM). The inhibition constants for pyrimethamine increased from 0.19 +/- 0.08 nM (3D7) to 2.0 +/- 0.3 nM (HB3) to 8.9 +/- 0.8 nM (7G8). The inhibition by pyrimethamine of the sensitive clone 3D7 was noncompetitive and competitive for the two other clones. The titration of partially purified DHFR with pyrimethamine revealed a 500-fold increase in the concentration of the drug needed to inhibit the DHFR activity by 50%, when the sensitive clone 3D7 (0.18 +/- 0.02 nM) was compared to the resistant clone 7G8 (95 +/- 16 nM). From the comparison of the specific activities and the catalytic center activities with the Km values for the substrate and the inhibition constants for pyrimethamine, both of which are altered in the resistant clones, we conclude that the molecular mechanism for pyrimethamine resistance in the three clones studied is not based on an overproduction of the DHFR but is due to a decreased affinity to antifolates by a structurally altered enzyme.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3553892

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Antifolate drug selection results in duplication and rearrangement of chromosome 7 in Plasmodium chabaudi.

Authors:  A F Cowman; A M Lew
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

Review 2.  Trimethoprim resistance.

Authors:  P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.

Authors:  D S Peterson; D Walliker; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 5.  Exploring the folate pathway in Plasmodium falciparum.

Authors:  John E Hyde
Journal:  Acta Trop       Date:  2005-04-18       Impact factor: 3.112

6.  Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.

Authors:  Alyson M Auliff; John H Adams; Michael T O'Neil; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

Review 7.  Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.

Authors:  Rodrigo G Ducati; Hilda A Namanja-Magliano; Vern L Schramm
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

8.  Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition.

Authors:  Ping Wang; Qi Wang; Yonghong Yang; James K Coward; Alexis Nzila; Paul F G Sims; John E Hyde
Journal:  Mol Biochem Parasitol       Date:  2010-03-27       Impact factor: 1.759

9.  Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro.

Authors:  Conner I Sandefur; Jason M Wooden; Isaac K Quaye; Worachart Sirawaraporn; Carol Hopkins Sibley
Journal:  Mol Biochem Parasitol       Date:  2007-03-20       Impact factor: 1.759

10.  Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.

Authors:  Vishal Patel; Michael Booker; Martin Kramer; Leila Ross; Cassandra A Celatka; Leah M Kennedy; Jeffrey D Dvorin; Manoj T Duraisingh; Piotr Sliz; Dyann F Wirth; Jon Clardy
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.